Written question asked by Daisy Cooper (Liberal Democrat) on Friday, 28 August 2026, in the House of Commons. It was due for an answer on Wednesday, 2 September 2026. It was answered by James Frith (Labour) on Tuesday, 22 September 2026 on behalf of the Department of Health and Social Care.
Brain: Tumours
- Question
-
To ask the Secretary of State for Health and Social Care, whether she will make representations to NuvationBio to encourage access to the SIGMA Phase 3 trial of Safusideniv for eligible patients at UK hospitals.
- Answer
-
The Department is supporting engagement with commercial sponsors of clinical trials through the National Institute for Health and Care Research (NIHR) Life Sciences Industry Hub. The NIHR Industry Hub provides a single, nationally coordinated pathway for research sponsors like Nuvation Bio to engage with, to set up and deliver commercial clinical trials.
Secondary information
- Type
- Written question
- Reference
- 21813
- Session
- 2026-27
- Grouped for answer
- Yes
- Subjects
- Eligibility Brain Clinical trials Tumours Nuvation Bio
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-10-09 16:36:11 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/21813
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/21813
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/21813